Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8786 results

  1. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development Reference number: GID-TA10486 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]

    Awaiting development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Transverse Tibial Transport

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. CT guided fibrin glue sealing of CSF leak to treat spontaneous intracranial hypotension

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. NEMOST growing domino for Neuromuscular early onset scoliosis with Risser 0 in first surgical intention

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]

    Awaiting development Reference number: GID-TA10879 Expected publication date:  11 November 2026

    Technology appraisal guidance
    Awaiting development

  10. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]

    Awaiting development Reference number: GID-TA11968 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704]

    Awaiting development Reference number: GID-TA11948 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

    In development Reference number: GID-TA11823 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  15. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation